Biogen (BIIB)
(Delayed Data from NSDQ)
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 7:10 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Biogen Inc. (BIIB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$283.56 | $350.00 | $200.00 | 24.67% |
Price Target
Based on short-term price targets offered by 27 analysts, the average price target for Biogen Inc. comes to $283.56. The forecasts range from a low of $200.00 to a high of $350.00. The average price target represents an increase of 24.67% from the last closing price of $227.44.
Analyst Price Targets (27)
Broker Rating
Biogen Inc. currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 30 brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on 30 recommendations.
Of the 30 recommendations deriving the current ABR, 19 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 63.33% and 6.67% of all recommendations. A month ago, Strong Buy made up 63.33%, while Buy represented 6.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BIIB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 19 | 19 |
Buy | 2 | 2 | 2 | 2 | 3 |
Hold | 9 | 9 | 9 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.68 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/16/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
7/12/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
7/9/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
7/3/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
6/24/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
6/12/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/7/2024 | Atlantic Equities | Steven K Chesney | Hold | Hold |
5/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/25/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/25/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/24/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
4/24/2024 | BTIG | Thomas Shrader | Hold | Hold |
4/19/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/17/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
4/17/2024 | UBS | Colin N Bristow | Hold | Hold |
4/4/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
2/23/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
2/22/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/20/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
2/20/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Strong Buy | Strong Buy |
2/14/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
2/14/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
12/14/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
11/9/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 30 |
Average Target Price | $283.56 |
LT Growth Rate | 6.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | 4.00 |